Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:50:56 EST Wed 17 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ICCM - ICECURE MEDICAL LTD - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ICCM - Q2.00.61·0.65894.20.6257-0.0143-2.2386.72213990.648  0.6493  0.61021.66  0.5918:50:30Dec 1015 min RT 2¢

Recent Trades - Last 10 of 399
Time ETExPriceChangeVolume
18:50:30Q0.6323-0.0077100
18:09:33Q0.6208-0.01921,300
17:13:58Q0.6365-0.00353
17:02:56Q0.6301-0.009910
16:04:15Q0.6257-0.01431
16:00:02Q0.6257-0.01432,245
16:00:02Q0.6257-0.01431,000
15:59:59Q0.6286-0.011477
15:59:57Q0.6295-0.0105100
15:59:57Q0.6284-0.0116100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-10 08:30U:ICCMNews ReleaseIceCure's ProSense(TM) Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
2025-12-05 08:30U:ICCMNews ReleaseIceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
2025-11-19 08:30U:ICCMNews ReleaseIceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
2025-11-18 08:30U:ICCMNews ReleaseIceCure's ProSense(TM) Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
2025-11-14 16:30U:ICCMNews ReleaseIceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
2025-11-12 08:30U:ICCMNews ReleaseIceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
2025-11-10 08:30U:ICCMNews ReleaseIceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
2025-11-03 08:30U:ICCMNews ReleaseIceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
2025-10-13 08:30U:ICCMNews ReleaseIceCure's ProSense(TM) Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
2025-10-09 08:30U:ICCMNews ReleaseIceCure Medical to Attend the 2025 Maxim Growth Summit
2025-10-03 12:28U:ICCMNews ReleaseIceCure Medical's ProSense(TM) Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
2025-10-03 12:19U:ICCMNews ReleaseIceCure Receives FDA Marketing Authorization for ProSense(TM) Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
2025-09-30 08:30U:ICCMNews ReleaseIceCure's ProSense(TM) at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
2025-09-22 08:30U:ICCMNews ReleaseIceCure's ProSense(TM) Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
2025-09-18 08:30U:ICCMNews ReleaseIceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense(TM) Cryoprobes
2025-09-15 08:30U:ICCMNews ReleaseIceCure Receives Regulatory Approval in Israel for its Next-Generation XSense(TM) Cryoablation System for Breast Cancer and Other Indications
2025-09-04 08:30U:ICCMNews ReleaseIceCure's ProSense(TM) Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
2025-08-13 08:30U:ICCMNews ReleaseIceCure Reports Financial & Operational Results for the First Half of 2025
2025-08-06 08:30U:ICCMNews ReleaseIceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
2025-07-29 09:00U:ICCMNews ReleaseIceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million